“Does Arterial Spin-labeling MR Imaging–measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?” Radiology 2009;251(3):731–742
On page 735, Figure 3, the left image in the third row is incorrect. The correct image is shown below, and arrows indicate copious microvasculature.
“Pulmonary Embolism Detection with Dual-Energy CT: Experimental Study of Dual-Source CT in Rabbits.” Radiology 2009;252(1):61–70
Page 62, the second sentence of the second paragraph should read as follows: In technologic terms, it is difficult to evaluate microcirculation of the whole lung with earlier-generation CT scanners, including single-source 64-section CT units, because of postprocessing time and misregistration artifacts between two spiral scanners (8–14).
Page 63, the first sentence under “Image Reconstruction and Analysis” should read as follows: From the raw spiral projection data acquired with both x-ray tubes, images were automatically reconstructed into three data sets (an 80-kVp data set, a 140-kVp data set, and a data set of fused images with 30% attenuation information from the 80-kVp scan and 70% attenuation information from the 140-kVp scan) with a 0.75-mm section thickness and a 0.50-mm section interval (33% overlap).
Page 68, left column, the first full sentence should read as follows: Our pilot study with rabbits showed that BF imaging alone had a diagnostic sensitivity of 89% in the detection of PE and had good agreement with pathologic analysis.
“Carotid Artery Brain Aneurysm Model: In Vivo Molecular Enzyme-specific MR Imaging of Active Inflammation in a Pilot Study.” Radiology 2009;252(3):696–703
Page 696, the fourth sentence of Materials and Methods should read as follows: After intraarterial injection of an MPO-specific (di-5-hydroxytryptamide of gadopentetate dimeglumine, 0.1 mmol per kilogram of bodyweight) or a non–MPO-specific (dityramide of gadopentetate dimeglumine, 0.1 mmol/kg) contrast agent, animals underwent 3-T MR imaging.
Page 696, the third sentence of Results should read as follows: In inflamed aneurysms, di-5-hydroxytryptamide of gadopentetate dimeglumine exhibited delayed washout kinetics compared with the kinetics of dityramide of gadopentetate dimeglumine.
Page 698, the first sentence under “MPO-specific and Non–MPO-specific Contrast Agents” should read as follows: An author (A.A.B., 18 years of experience) performed synthesis of MPO-specific (di-5-hydroxytryptamide of gadopentetate dimeglumine) and non–MPO-specific (dityramide of gadopentetate dimeglumine) MR contrast agents, as described previously (24,25), with slight modifications.
Page 698, right column, the third full sentence should read as follows: Animals were then injected with a sterile solution of 0.1 mmol/kg of di-5-hydroxytryptamide of gadopentetate dimeglumine or dityramide of gadopentetate dimeglumine in 15 mL of 5% meglumine with a pH of 7.
Page 698, right column, the fifth full sentence should read as follows: Time course experiments were performed up to 330 minutes after contrast agent injection with the same imaging parameters described previously after administration of either di-5-hydroxytryptamide of gadopentetate dimeglumine or dityramide of gadopentetate dimeglumine in animals with aneurysms into which LPS had been injected.
Page 699, the first sentence under “Sensitivity and Specificity for MPO in Inflamed Aneurysms” should read as follows: The kinetics of enhancement of the aneurysm and left CCA with both di-5-hydroxytryptamide of gadopentetate dimeglumine and dityramide of gadopentetate dimeglumine are shown in Figure 3.
Page 699, the third sentence under “Sensitivity and Specificity for MPO in Inflamed Aneurysms” should read as follows: Both the inflamed aneurysm and the left CCA in the animal that received dityramide of gadopentetate dimeglumine had similar enhancement ratios measured at each point of the time course.
Page 701, the caption for figure 3 should read as follows: Figure 3: Graphs show kinetics of enhancement of (a) a representative LPS-injected aneurysm and (b) the left CCA. The enhancement ratio (ER) of di-5-hydroxytryptamide of gadopentetate dimeglumine (di-5-HT-GdDTPA) is compared with that of dityramide of gadopentetate dimeglumine (di-Tyr-GdDTPA).
Page 702, left column, second paragraph, the third sentence should read as follows: We compared the observed enhancement ratio with that of dityramide of gadopentetate dimeglumine, which is a contrast agent that is structurally similar to di-5-hydroxytryptamide of gadopentetate dimeglumine and has been demonstrated in vitro to be activated by peroxidases but not by MPO (24).